MaxCyte, Inc.
MXCT
Rank in Stocks
#18754
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes... MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Share Price
$1.19
Last synced: 2026-11-13
Market Cap
$123.21M
Change (1 day)
0.00%
Change (1 year)
-24.68%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MaxCyte, Inc. (MXCT)
Category
Healthcare
Number of shares outstanding for MaxCyte, Inc. (MXCT)
Number of shares outstanding as of September 2026: 103.54M
According to MaxCyte, Inc.'s latest financial reports, its current number of shares outstanding is 103.54M. At the end of 2025 the company had 106.43M shares outstanding. The number of shares outstanding usually changes with stock splits and share buybacks.
Shares outstanding history for MaxCyte, Inc. (MXCT) from 2012 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 103.54M | -2.72% |
| 2025 | 106.43M | 1.51% |
| 2024 | 104.85M | 1.53% |
| 2023 | 103.27M | 1.54% |
| 2022 | 101.70M | 12.23% |
| 2021 | 90.62M | 30.45% |
| 2020 | 69.46M | 23.17% |
| 2019 | 56.40M | 10.19% |
| 2018 | 51.18M | 5.22% |
| 2017 | 48.64M | 45.13% |
| 2016 | 33.52M | -22.90% |
| 2015 | 43.47M | 3,669.96% |
| 2014 | 1.15M | -97.35% |
| 2013 | 43.47M | 0.00% |
| 2012 | 43.47M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 64.62B | 62,312.04% |
US
|
|
| 253.50M | 144.84% |
US
|
|
| 401.00M | 287.30% |
US
|
|
| 478.91M | 362.55% |
AU
|
|
| 0.00 | -100.00% |
BE
|
Questions about MaxCyte, Inc.'s number of shares outstanding
What is MaxCyte, Inc.'s number of shares outstanding?
MaxCyte, Inc.'s number of shares outstanding is 103.54M, as of Sep 2026.
What was MaxCyte, Inc.'s number of shares outstanding in 2025?
In 2025, MaxCyte, Inc.'s number of shares outstanding was 106.43M, 1.51% more than in 2024 (104.85M).
How has MaxCyte, Inc.'s number of shares outstanding changed since 2020?
From 2020 to 2025, MaxCyte, Inc.'s number of shares outstanding went from 69.46M to 106.43M, an average growth of 8.91% a year.